ASCO: UT MD Anderson spotlights emerging precision therapies for rare and difficult-to-treat cancers
ABSTRACTS: 8510, 8008, 6009, 4520
Researchers at The University of Texas MD Anderson Cancer Center will present new findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showcasing innovative targeted therapies for several rare and hard-to-treat cancers. Presentations feature precision treatments with promising early results across multiple tumor types, including lung cancer, adenoid cystic carcinoma...
Researchers identify drivers of resistance to KRAS inhibitors in colorectal cancer
Colorectal cancer can resist KRAS inhibitors in both genetic and non-genetic ways
An early inflammation surge within days of treatment helps...
Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy
Patients with metastatic castration-resistant prostate cancer who do not benefit from chemotherapy need more effective treatment options
Phase...
Tumor microenvironment features may predict immunotherapy response in rare cancers
Phase 2 trial investigated the effectiveness of pembrolizumab (Keytruda) in rare cancers
Overall responses were modest, but analysis showed new potential biomarkers beyond the current genomic markers of response
These biomarkers could expand benefits of immunotherapy to patients who previously would not have been expected to respond
A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center...
ESTRO: ctDNA improves treatment monitoring for patients receiving metastasis-directed therapy
Analysis from the Phase 2 EXTEND trial showed ctDNA testing provided new insights into treatment response for patients receiving metastasis-directed...
ESTRO: Select breast cancer patients may be able to omit surgery following ablative radiation
Patients in this trial eligible to avoid surgery had a disease control rate of 100% at a median follow-up of over three years ...
New marker aids diagnosis for aggressive prostate cancer
Aggressive prostate cancers often lose expression of traditional markers after treatment, making it hard to diagnose the tumor’s origin and...
Study may help predict response to chemotherapy in triple-negative breast cancer
Triple-negative breast cancer is treated with chemotherapy, but outcomes vary significantly among patients
Tumors have unique characteristics...
Low-intensity combination therapy yields strong outcomes in hard-to-treat AML
Researchers combined an alternating regimen of lower-intensity therapy with a targeted agent in older or medically fragile patients with newly...
RAS inhibitor daraxonrasib demonstrates initial anti-tumor activity in pancreatic cancer
Daraxonrasib is an oral, multi-selective RAS inhibitor from Revolution Medicines
Data from this trial previously prompted the Food and Drug...
Scientists find blood-based biomarkers for inflammatory breast cancer
Inflammatory breast cancer (IBC) is highly aggressive, but there are no known genomic differences that can tell it apart from other breast cancers...
Researchers find biomarker of chemotherapy resistance in relapsed lung cancer
Standard chemotherapy treatment for small cell lung cancer (SCLC) often leads to resistance and eventual relapse
The YAP1 protein emerges in...
Tumor markers in rare appendiceal cancer may predict treatment outcomes
Researchers monitored levels of common blood markers before and after surgery to remove cancer
Study found...
Researchers find potential one-two punch against triple-negative breast cancer
Many breast cancer therapies work by causing DNA replication stress, but triple-negative breast cancer (TNBC) cells survive this stress, even...